valproic acid has been researched along with Hyperammonemia in 182 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Hyperammonemia: Elevated level of AMMONIA in the blood. It is a sign of defective CATABOLISM of AMINO ACIDS or ammonia to UREA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyperammonemia can occur after acute overdose or chronic use of valproic acid (VPA)." | 9.41 | Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy. ( Kim, DW; Kwack, DW, 2023) |
| "Valproate (VPA) administration may be associated with adverse metabolic effects, among is hyperammonemia, which could suggest metabolic abnormalities as carnitine deficiency." | 9.14 | The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. ( Abdella, MM; Hamed, SA, 2009) |
| "Valproic acid (VPA) is frequently used in the treatment of epilepsy." | 9.01 | CPS1 T1405N polymorphism, HDL cholesterol, homocysteine and renal function are risk factors of VPA induced hyperammonemia among epilepsy patients. ( Chen, D; Chen, L; Chen, P; Gao, X; Li, C; Li, H; Li, Y; Tian, Q; Tian, X; Wen, J; Yang, H; Zhang, M, 2019) |
| "Resolution of hyperammonemia caused by Valproic acid therapy may be enhanced with the administration of L-carnitine." | 8.95 | Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report. ( Ballabio, M; Cattaneo, CI; D'Innella, P; Fornaro, M; Ressico, F; Valsesia, R, 2017) |
| "Valproic acid (VPA)-induced hyperammonemia (HA) is a rare adverse effect reported even at therapeutic VPA levels." | 8.31 | Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey. ( Aghamollaii, V; Ghayyem, H; Hassani, M; Hosseini, H; Mayeli, M; Shafie, M; Shakiba, A, 2023) |
| "AbstractThe aim of this study was to explore the effect of lamotrigine (LTG) on blood ammonia level in patients with epilepsy and identify risk factors affecting blood ammonia level." | 8.12 | Risk factors of elevated blood ammonia level in epilepsy patients treated with lamotrigine. ( Chen, J; Chen, X; Chen, Y; Miao, J; Wang, R; Zeng, J; Zhuang, X, 2022) |
| " Both levocarnitine and lactulose, either alone or in combination, have been used for the treatment of hyperammonemia associated with valproic acid, however they have not been directly compared in the literature." | 8.02 | Evaluation of levocarnitine, lactulose, and combination therapy for the treatment of valproic acid-induced hyperammonemia in critically ill patients. ( Cunningham, B; Fowler, M; Mullen, C; Nicholson, C, 2021) |
| "Hyperammonemia is a common side effect of valproic acid (VPA) and can occur after generalized seizures, but the clinical significance is unclear." | 8.02 | Hyperammonemia in Patients With Status Epilepticus Treated With or Without Valproic Acid. ( Britton, JW; Hocker, SE; Smith, KM; Toledano, M, 2021) |
| "In this report, we describe the diagnosis, investigation and management of a patient presenting with refractory status epilepticus secondary to a previously unrecognised urea cycle defect, ornithine transcarbamylase deficiency, causing a hyperammonaemic encephalopathy." | 8.02 | Status epilepticus secondary to hyperammonaemia: a late presentation of an undiagnosed urea cycle defect. ( Beddoes, P; Nerone, G; Tai, C, 2021) |
| "The aim of the study was to examine the frequency of hyperammonemia secondary to valproic acid treatment in status epilepticus and to describe the characteristics of the patients." | 7.91 | Intravenous use of valproic acid in status epilepticus is associated with high risk of hyperammonemia. ( Lind, J; Nordlund, P, 2019) |
| "This study was aimed at identifying genetic and non-genetic risk factors for valproic acid (VPA)-induced hyperammonaemia in Chinese paediatric patients with epilepsy." | 7.88 | Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy. ( Li, X; Zhang, T; Zhao, L; Zhu, X, 2018) |
| "Valproic acid (VPA) is an FDA-approved medication widely prescribed for seizures, migraines, and mixed or manic episodes in bipolar disorder." | 7.85 | Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report. ( Birur, B; Fargason, RE; Landry, KB; Patel, N, 2017) |
| "Our purpose was to evaluate the relationship between valproic acid (VPA)-induced hyperammonemia (HA) and the prevalence of minimal hepatic encephalopathy (MHE) cognitive impairment among psychiatric inpatients." | 7.83 | Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients. ( Doroudgar, S; La, AQ; Perry, PJ; Punia, S; Thomas, KL, 2016) |
| "Carnitine deficiency is relatively common in epilepsy; risk factors reportedly include combination antiepileptic drug (AED) therapy with valproic acid (VPA), young age, intellectual disability, diet and enteral or parenteral feeding." | 7.81 | Carnitine deficiency: Risk factors and incidence in children with epilepsy. ( Fukuda, M; Ishii, E; Iwano, S; Kawabe, M; Kikuchi, C; Kuwabara, K; Morimoto, T; Suzuki, Y; Takehara, M; Wakamoto, H, 2015) |
| "Valproic acid (VPA), which is widely used to treat epilepsy, migraine, and bipolar disorder, can causes severe hyperammonemia." | 7.81 | Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy. ( Hirai, K; Imai, K; Inoue, K; Inoue, Y; Itoh, K; Suzuki, E; Takahashi, T; Takahashi, Y; Tsuji, D; Yamamoto, Y, 2015) |
| "Valproic acid, a branched short-chain fatty acid, has numerous action mechanisms which turn it into a broad spectrum anticonvulsant drug and make its use possible in some other pathologies such as bipolar disorder." | 7.80 | Hyperammonemia associated with valproic acid concentrations. ( Alvariza, S; Fagiolino, P; Guevara, N; Ibarra, M; Magallanes, L; Maldonado, C; Olano, I; Olmos, I; Vázquez, M, 2014) |
| "Valproic acid, which is widely used to treat various types of epilepsy, may cause severe hyperammonemia." | 7.80 | 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy. ( Hayashi, H; Imai, K; Inoue, K; Inoue, Y; Itoh, K; Miyakawa, K; Suzuki, E; Takahashi, T; Takahashi, Y; Tsuji, D; Yamamoto, Y; Yazawa, R, 2014) |
| "Hyperammonemia has been reported to be associated with patients who receive valproic acid (VPA) therapy." | 7.80 | Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy. ( Chang, CC; Chang, WN; Chen, NC; Chuang, YC; Huang, CR; Lin, CH; Lu, CH; Lu, YT; Tseng, YL, 2014) |
| "Hyperammonemia is one of the side effects of treatment with valproic acid (VPA), but the risk factors and mechanisms involved remain obscure." | 7.78 | Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients. ( Inoue, K; Inoue, Y; Itoh, K; Kagawa, Y; Mishima, N; Suzuki, E; Takahashi, Y; Yamamoto, Y, 2012) |
| "Valproic acid (VPA) is associated with hyperammonemia; however, little is known about this phenomenon in the geriatric psychiatric population." | 7.78 | Hyperammonemia associated with valproic acid use in elderly psychiatric patients. ( Holroyd, S; Overdyke, JT, 2012) |
| "This is the first report of mixed respiratory alkalosis and metabolic acidosis in a child treated with sulthiame." | 7.76 | Respiratory alkalosis and metabolic acidosis in a child treated with sulthiame. ( Garty, BZ; Hoffer, V; Scheuerman, O; Tirosh, I; Weissbach, A, 2010) |
| "This case report describes two children who developed hyperammonemia together with frank manic behavior during treatment with a combination of valproic acid and risperidone." | 7.74 | Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania. ( Caplan, R; Carlson, T; Reynolds, CA, 2007) |
| " However, he was found to have hyperammonemia within 2 weeks after the addition of low-dose topiramate to valproate." | 7.73 | Topiramate-valproate-induced hyperammonemic encephalopathy syndrome: case report. ( Cheung, E; Fung, CW; Wong, V, 2005) |
| "Valproic acid has been widely used for the treatment of epilepsy." | 7.73 | [Hyperammonemia secondary to the use of valproic acid: case report]. ( Fernandes, RM; Funayama, CA; Turcato, Mde F; Wichert-Ana, L, 2005) |
| "To describe a case of oral valproic acid-induced hyperammonemia and thrombocytopenia in an elderly patient." | 7.72 | Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman. ( Babin, S; Mallet, L; Morais, JA, 2004) |
| "Valproic acid (VPA) is a short-chain fatty acid widely prescribed in the treatment of seizure disorders and epilepsy syndromes, although its therapeutic value may be undermined by its toxicity." | 5.91 | Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation. ( Fagiolino, P; Ibarra, M; Maldonado, C; Schiavo, A; Trocóniz, IF; Vázquez, M, 2023) |
| "Results: Mild cognitive impairment - MCI was diagnosed in 4 patients (28." | 5.72 | HYPERAMMONAEMIA AND COGNITIVE IMPAIRMENT IN EPILEPSY PATIENTS TREATED WITH VALPROIC ACID - PRELIMINARY STUDY. ( Dutkiewicz, J; Pilut, D; Szczygieł-Pilut, EE; Zajączkowska-Dutkiewicz, A, 2022) |
| "Carnitine is a commonly used antidote for acute intoxication of valproic acid, but is not a therapeutic option for management of chronic adults with adverse effects related to valproic acid." | 5.46 | L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report. ( Fagiolino, P; Guevara, N; Maldonado, C; Silveira, A; Vázquez, M, 2017) |
| "Hyperammonemia can occur after acute overdose or chronic use of valproic acid (VPA)." | 5.41 | Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy. ( Kim, DW; Kwack, DW, 2023) |
| "We present a case of hyperammonaemic coma precipitated by sodium valproate use for symptomatic epilepsy in a patient with unrecognised portosystemic shunt, secondary to earlier alcoholism." | 5.39 | Valproic acid-induced hyperammonaemic coma and unrecognised portosystemic shunt. ( Basilio, C; Carrapatoso, L; Ferreira, F; Nzwalo, H, 2013) |
| "A 56-year-old woman with poorly controlled epilepsy, receiving valproate at subtherapeutic levels for 6 years, developed a life-threatening hyperammonemic coma following a moderate dosage increase." | 5.33 | Acute hyperammonemic coma with chronic valproic acid therapy. ( Abramson, RK; Cuturic, M, 2005) |
| "We describe the case of a 56-year-old man who presented to the emergency department after an intentional VPA overdose, was found to have hyperammonemia, and was treated with L-carnitine exclusively." | 5.22 | Valproic Acid Overdose: Case Report and Literature Review. ( Berezowski, I; Frasure, SE; Mazer-Amirshahi, M; Patel, J; Pourmand, A; Tran, QK, 2022) |
| "Valproic acid (VPA) has been associated with hyperammonemia with and without encephalopathy." | 5.14 | Hyperammonemia following intravenous valproate loading. ( Beasley, MT; Cofield, S; DeWolfe, JL; Faught, E; Knowlton, RC; Limdi, NA, 2009) |
| "Valproate (VPA) administration may be associated with adverse metabolic effects, among is hyperammonemia, which could suggest metabolic abnormalities as carnitine deficiency." | 5.14 | The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status. ( Abdella, MM; Hamed, SA, 2009) |
| "Valproic acid (VPA) is frequently used in the treatment of epilepsy." | 5.01 | CPS1 T1405N polymorphism, HDL cholesterol, homocysteine and renal function are risk factors of VPA induced hyperammonemia among epilepsy patients. ( Chen, D; Chen, L; Chen, P; Gao, X; Li, C; Li, H; Li, Y; Tian, Q; Tian, X; Wen, J; Yang, H; Zhang, M, 2019) |
| "Resolution of hyperammonemia caused by Valproic acid therapy may be enhanced with the administration of L-carnitine." | 4.95 | Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report. ( Ballabio, M; Cattaneo, CI; D'Innella, P; Fornaro, M; Ressico, F; Valsesia, R, 2017) |
| "Valproic acid is a widely-used first-generation antiepileptic drug, prescribed predominantly in epilepsy and psychiatric disorders." | 4.89 | Adverse drug reactions induced by valproic acid. ( Nanau, RM; Neuman, MG, 2013) |
| "Valproic acid (VPA)-induced hyperammonemia (HA) is a rare adverse effect reported even at therapeutic VPA levels." | 4.31 | Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey. ( Aghamollaii, V; Ghayyem, H; Hassani, M; Hosseini, H; Mayeli, M; Shafie, M; Shakiba, A, 2023) |
| "Valproic acid is an effective mood stabilizer, registered for the treatment of bipolar disorder and epilepsy." | 4.31 | [A severe, reversible encephalopathy after prolonged use of valproic acid]. ( Bloemkolk, D; Gerritse, FL; Rundervoort, RS; van Haaren, PCF, 2023) |
| "We present a case of a 29-year-old female with a history of epilepsy who was admitted for convulsive status epilepticus (CSE), which was controlled by intravenous VPA, as well as oral VPA and phenytoin." | 4.31 | Valproate-related hyperammonemic encephalopathy with generalized suppression EEG: a case report. ( Liu, X; Peng, X, 2023) |
| "AbstractThe aim of this study was to explore the effect of lamotrigine (LTG) on blood ammonia level in patients with epilepsy and identify risk factors affecting blood ammonia level." | 4.12 | Risk factors of elevated blood ammonia level in epilepsy patients treated with lamotrigine. ( Chen, J; Chen, X; Chen, Y; Miao, J; Wang, R; Zeng, J; Zhuang, X, 2022) |
| " Both levocarnitine and lactulose, either alone or in combination, have been used for the treatment of hyperammonemia associated with valproic acid, however they have not been directly compared in the literature." | 4.02 | Evaluation of levocarnitine, lactulose, and combination therapy for the treatment of valproic acid-induced hyperammonemia in critically ill patients. ( Cunningham, B; Fowler, M; Mullen, C; Nicholson, C, 2021) |
| "Hyperammonemia is a common side effect of valproic acid (VPA) and can occur after generalized seizures, but the clinical significance is unclear." | 4.02 | Hyperammonemia in Patients With Status Epilepticus Treated With or Without Valproic Acid. ( Britton, JW; Hocker, SE; Smith, KM; Toledano, M, 2021) |
| "In this report, we describe the diagnosis, investigation and management of a patient presenting with refractory status epilepticus secondary to a previously unrecognised urea cycle defect, ornithine transcarbamylase deficiency, causing a hyperammonaemic encephalopathy." | 4.02 | Status epilepticus secondary to hyperammonaemia: a late presentation of an undiagnosed urea cycle defect. ( Beddoes, P; Nerone, G; Tai, C, 2021) |
| "The aim of the study was to examine the frequency of hyperammonemia secondary to valproic acid treatment in status epilepticus and to describe the characteristics of the patients." | 3.91 | Intravenous use of valproic acid in status epilepticus is associated with high risk of hyperammonemia. ( Lind, J; Nordlund, P, 2019) |
| "This study was aimed at identifying genetic and non-genetic risk factors for valproic acid (VPA)-induced hyperammonaemia in Chinese paediatric patients with epilepsy." | 3.88 | Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy. ( Li, X; Zhang, T; Zhao, L; Zhu, X, 2018) |
| "This 13-year-old girl with autism and intractable epilepsy experienced increased seizures; her valproic acid dose was increased and other antiepileptic drugs were administered." | 3.85 | Burst Suppression Pattern on Electroencephalogram Secondary to Valproic Acid-Induced Hyperammonemic Encephalopathy. ( Cherian, KA; Legatt, AD, 2017) |
| "Valproic acid (VPA) is an FDA-approved medication widely prescribed for seizures, migraines, and mixed or manic episodes in bipolar disorder." | 3.85 | Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report. ( Birur, B; Fargason, RE; Landry, KB; Patel, N, 2017) |
| ", drowsiness, coma) were selected for treatment with l-arginine." | 3.85 | L-Arginine in the treatment of valproate overdose - five clinical cases. ( Eyer, F; Felgenhauer, N; Fernando, M; Rabe, C; Schrettl, V, 2017) |
| "Our purpose was to evaluate the relationship between valproic acid (VPA)-induced hyperammonemia (HA) and the prevalence of minimal hepatic encephalopathy (MHE) cognitive impairment among psychiatric inpatients." | 3.83 | Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients. ( Doroudgar, S; La, AQ; Perry, PJ; Punia, S; Thomas, KL, 2016) |
| "We report the case of an aborted awake craniotomy for a left frontotemporoinsular glioma due to ammonia encephalopathy on a patient taking Levetiracetam, valproic acid and clobazam." | 3.81 | Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy. ( Arroyo Pérez, R; Fernández-Candil, JL; León Jorba, A; Pacreu Terradas, S; Villalba Martínez, G; Vivanco-Hidalgo, RM, 2015) |
| "Carnitine deficiency is relatively common in epilepsy; risk factors reportedly include combination antiepileptic drug (AED) therapy with valproic acid (VPA), young age, intellectual disability, diet and enteral or parenteral feeding." | 3.81 | Carnitine deficiency: Risk factors and incidence in children with epilepsy. ( Fukuda, M; Ishii, E; Iwano, S; Kawabe, M; Kikuchi, C; Kuwabara, K; Morimoto, T; Suzuki, Y; Takehara, M; Wakamoto, H, 2015) |
| "The purpose of the present study was to examine the relationship between the incidence of hyperammonemia and changes in the prescribing of concomitant antiepileptic drugs (AEDs) in patients receiving valproic acid." | 3.81 | Changing incidence of hyperammonemia in Japan from 2006 to 2013: expansion of new antiepileptic drugs reduces the risk of hyperammonemia. ( Imai, K; Inoue, Y; Kagawa, Y; Mishima, N; Takahashi, Y; Yamamoto, Y, 2015) |
| "Valproic acid (VPA), which is widely used to treat epilepsy, migraine, and bipolar disorder, can causes severe hyperammonemia." | 3.81 | Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy. ( Hirai, K; Imai, K; Inoue, K; Inoue, Y; Itoh, K; Suzuki, E; Takahashi, T; Takahashi, Y; Tsuji, D; Yamamoto, Y, 2015) |
| "Valproic acid, a branched short-chain fatty acid, has numerous action mechanisms which turn it into a broad spectrum anticonvulsant drug and make its use possible in some other pathologies such as bipolar disorder." | 3.80 | Hyperammonemia associated with valproic acid concentrations. ( Alvariza, S; Fagiolino, P; Guevara, N; Ibarra, M; Magallanes, L; Maldonado, C; Olano, I; Olmos, I; Vázquez, M, 2014) |
| "Valproic acid, which is widely used to treat various types of epilepsy, may cause severe hyperammonemia." | 3.80 | 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy. ( Hayashi, H; Imai, K; Inoue, K; Inoue, Y; Itoh, K; Miyakawa, K; Suzuki, E; Takahashi, T; Takahashi, Y; Tsuji, D; Yamamoto, Y; Yazawa, R, 2014) |
| "Hyperammonemia has been reported to be associated with patients who receive valproic acid (VPA) therapy." | 3.80 | Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy. ( Chang, CC; Chang, WN; Chen, NC; Chuang, YC; Huang, CR; Lin, CH; Lu, CH; Lu, YT; Tseng, YL, 2014) |
| " Ten patients on valproic acid therapy of any age group with idiopathic or secondary epilepsy, who presented with encephalopathic symptoms, were registered and followed up during the study." | 3.79 | Valproic acid induced hyperammonaemic encephalopathy. ( Amanat, S; Hassan, Y; Shahbaz, N, 2013) |
| "Case one describes an adult male who developed hyperammonemia after acute exposure to valproic acid as a treatment for his bipolar disorder-manic episode." | 3.79 | Hyperammonemia induced by interaction of valproate and quetiapine. ( Haddad, R; Halaby, A; Naja, WJ, 2013) |
| "Hyperammonemia is one of the side effects of treatment with valproic acid (VPA), but the risk factors and mechanisms involved remain obscure." | 3.78 | Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients. ( Inoue, K; Inoue, Y; Itoh, K; Kagawa, Y; Mishima, N; Suzuki, E; Takahashi, Y; Yamamoto, Y, 2012) |
| "Valproic acid (VPA) is associated with hyperammonemia; however, little is known about this phenomenon in the geriatric psychiatric population." | 3.78 | Hyperammonemia associated with valproic acid use in elderly psychiatric patients. ( Holroyd, S; Overdyke, JT, 2012) |
| "Hyperammonemia is a frequent side-effect of valproic acid (VPA) therapy, which points to an imbalance between ammoniagenesis and ammonia disposal via the urea cycle." | 3.77 | New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. ( Aires, CC; de Almeida, IT; Duran, M; Ijlst, L; Silva, MF; van Cruchten, A; Wanders, RJ, 2011) |
| "In order to clarify the factors causing hyperammonemia and to predict occurrences during treatment with valproic acid (VPA), we investigated the effect of the genetic polymorphism of carbamoyl-phosphate synthase 1 (CPS14217C>A) on susceptibility of hyperammonemia, together with the effect of coadministration of other anticonvulsants." | 3.76 | Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia. ( Kawasaki, Y; Matsuo, M; Nakamura, T; Okamura, N; Okizuka, Y; Okumura, K; Oyazato, Y; Sakaeda, T; Tsuneishi, S; Yagi, M, 2010) |
| "This is the first report of mixed respiratory alkalosis and metabolic acidosis in a child treated with sulthiame." | 3.76 | Respiratory alkalosis and metabolic acidosis in a child treated with sulthiame. ( Garty, BZ; Hoffer, V; Scheuerman, O; Tirosh, I; Weissbach, A, 2010) |
| "Valproate (VPA) interferes with mitochondrial metabolism causing hyperammonemia, thereby shifting the balance reaction of glutamine (Gln)/glutamate (Glu) toward Gln." | 3.75 | Valproate-induced metabolic changes in patients with epilepsy: assessment with H-MRS. ( Buechert, M; Garcia, M; Huppertz, HJ; Mader, I; Schumacher, M; Ziyeh, S, 2009) |
| "The authors describe a case of a drug-associated hyperammonemia, central pontine myelinolysis and coma occurring in a patient with Sjögren's syndrome chronically treated with valproic acid for an underlying psychotic disorder." | 3.74 | [Hyperammoniemia and central pontine myelinolysis in a patient with Sjögren syndrome and chronic valproate use]. ( Battaglia, K; Berlot, G; Ukmar, M, 2008) |
| "This case report describes two children who developed hyperammonemia together with frank manic behavior during treatment with a combination of valproic acid and risperidone." | 3.74 | Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania. ( Caplan, R; Carlson, T; Reynolds, CA, 2007) |
| "Two cases of acute valproic acid poisoning with central nervous system depression and raised ammonia level without hepatotoxicity were reported." | 3.74 | Two cases of valproic acid poisoning treated with L-carnitine. ( Chan, YC; Lau, FL; Tse, ML, 2007) |
| " However, he was found to have hyperammonemia within 2 weeks after the addition of low-dose topiramate to valproate." | 3.73 | Topiramate-valproate-induced hyperammonemic encephalopathy syndrome: case report. ( Cheung, E; Fung, CW; Wong, V, 2005) |
| "Valproic acid has been widely used for the treatment of epilepsy." | 3.73 | [Hyperammonemia secondary to the use of valproic acid: case report]. ( Fernandes, RM; Funayama, CA; Turcato, Mde F; Wichert-Ana, L, 2005) |
| "The aims of this report are to 1) present a rare case of fatal cerebral edema associated with late-onset ornithine transcarbamylase (OTC) deficiency in a juvenile male patient receiving valproic acid and 2) review the neuropathologic changes associated with the hyperammonemia." | 3.73 | Fatal cerebral edema from late-onset ornithine transcarbamylase deficiency in a juvenile male patient receiving valproic acid. ( Fraser, DD; Ramsay, DA; Rupar, CA; Singh, R; Thakur, V, 2006) |
| "To describe a case of oral valproic acid-induced hyperammonemia and thrombocytopenia in an elderly patient." | 3.72 | Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman. ( Babin, S; Mallet, L; Morais, JA, 2004) |
| "Serum or CSF glutamine levels are initially elevated in a majority of patients with suspected VHE, sometimes in the absence of hyperammonemia." | 3.71 | Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy. ( Cawthon, DF; Caylor, LM; Kraemer, DL; Morgan, JD; Ojemann, LM; Vossler, DG; Wilensky, AJ, 2002) |
| "We present three children with severe therapy-refractory epilepsy who tolerated valproate (VPA) well in various combinations with other antiepileptic drugs (AEDs) but developed typical VPA side effects in combination with topiramate (TPM)." | 3.71 | Topiramate enhances the risk of valproate-associated side effects in three children. ( Koelfen, W; König, S; Longin, E; Teich, M, 2002) |
| "Valproic acid-induced encephalopathy mainly manifests as acute or subacute encephalopathy and has been associated with hyperammonemia, L-carnitine deficiency, and urea cycle enzyme dysfunction." | 2.72 | Valproic acid-induced encephalopathy: A review of clinical features, risk factors, diagnosis, and treatment. ( Jing, W; Li, J; Tian, X; Wang, X; Wu, J, 2021) |
| "VPA is widely used for the treatment of generalized epilepsy." | 2.61 | [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy]. ( Araki, M; Mukai, T; Naka, H; Shishido, T; Tokinobu, H; Yamada, H, 2019) |
| " Hyperammonemic coma is determined through a complicated differential diagnosis, and although it can also be induced as a side effect of valproate (VPA), this cause is frequently unrecognized or confused with upper gastrointestinal hemorrhage (UGH)-induced hepatic encephalopathy." | 2.55 | Hyperammonemic coma after craniotomy: Hepatic encephalopathy from upper gastrointestinal hemorrhage or valproate side effect?: Case report and literature review. ( Gao, L; Guo, X; Wei, J; Xing, B; Xu, Z, 2017) |
| "Carnitine is an essential cofactor in the proper metabolism of valproic acid and ammonia elimination." | 2.48 | Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy. ( Mock, CM; Schwetschenau, KH, 2012) |
| "It is well-known that the patients with autosomal recessive juvenile Parkinsonism (ARJP), which is caused by the loss of function mutation in the Parkin gene, often show psychiatric symptoms such as depression, paranoia, psychosis, panic attacks, anorexia nervosa or suicide attempts." | 2.47 | [Pharmacogenetics focused on special phenotypes]. ( Sano, A, 2011) |
| "Carnitine is an amino acid derivative that is an essential cofactor in the beta-oxidation of fatty acids." | 2.45 | Carnitine in the treatment of valproic acid-induced toxicity. ( Hantson, P; Lheureux, PE, 2009) |
| "We report a 66-year-old man with hepatic encephalopathy due to a non-cirrhotic porto-systemic shunt during the course of treatment for epilepsy with sodium valproate." | 2.43 | [Successful balloon-occluded retrograde transvenous obliteration (B-RTO) in a case of symptomatic epilepsy with hepatic encephalopathy due to non-cirrhotic porto-systemic shunt]. ( Hayashi, S; Noguchi, M; Shibata, A, 2005) |
| "Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well tolerated, but rare serious complications may occur in some patients receiving VPA chronically, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity (VHT) and VPA-induced hyperammonaemic encephalopathy (VHE)." | 2.43 | Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? ( Gris, M; Lheureux, PE; Penaloza, A; Zahir, S, 2005) |
| "Valproic acid (VPA) is an effective anticonvulsant useful in many types of epilepsy and, although it is usually well tolerated, it has been associated with many neurological and systemic side effects." | 2.41 | Valproate-induced hyperammonemic encephalopathy. ( Chiarelli, F; Morgese, G; Trotta, D; Verrotti, A, 2002) |
| "Valproic acid (VPA) is a short-chain fatty acid widely prescribed in the treatment of seizure disorders and epilepsy syndromes, although its therapeutic value may be undermined by its toxicity." | 1.91 | Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation. ( Fagiolino, P; Ibarra, M; Maldonado, C; Schiavo, A; Trocóniz, IF; Vázquez, M, 2023) |
| "We present two cases of arginase deficiency with genetically confirmed ARG1 mutation in one and biochemical confirmation in both." | 1.91 | Arginase deficiency-An unheralded cause of developmental epileptic encephalopathy. ( Banerjee, M; Fasaludeen, A; Jose, M; Menon, RN; Pavuluri, H; Radhakrishnan, A; Sundaram, S, 2023) |
| "The patient developed hyperammonaemic encephalopathy due to sodium valproate overdose and was treated with supportive care and renal replacement therapy." | 1.91 | Valproate overdose leading to hyperammonaemic encephalopathy. ( Gupta, S; Sharma, DS; Sharma, P, 2023) |
| "Valproate-induced encephalopathy (VIE) affects between 0." | 1.91 | Acute Valproate-Induced Encephalopathy in Status Epilepticus: A Registry-Based Assessment. ( Beuchat, I; Loser, V; Novy, J; Rossetti, AO, 2023) |
| "Results: Mild cognitive impairment - MCI was diagnosed in 4 patients (28." | 1.72 | HYPERAMMONAEMIA AND COGNITIVE IMPAIRMENT IN EPILEPSY PATIENTS TREATED WITH VALPROIC ACID - PRELIMINARY STUDY. ( Dutkiewicz, J; Pilut, D; Szczygieł-Pilut, EE; Zajączkowska-Dutkiewicz, A, 2022) |
| "Levocarnitine is the treatment of choice in valproic acid toxicity-related hyperammonaemia." | 1.62 | Managing valproic acid toxicity-related hyperammonaemia: an unpredicted course. ( Edquist, C; O'Rourke, N; Pagali, S, 2021) |
| "Hyperammonemic encephalopathy is a rare and serious adverse reaction to valproate." | 1.56 | Valproate-induced hyperammonemic encephalopathy: a case report. ( Shah, S; Vieux, U; Wang, R, 2020) |
| " In children under 2 years old, serious adverse effects are appear to be more frequent." | 1.51 | Adverse Effects of Treatment with Valproic Acid during the Neonatal Period. ( Baudou, E; Benevent, J; Hachon LeCamus, C; Montastruc, JL; Touati, G, 2019) |
| "Hyperammonemic encephalopathy secondary to the use of valproate is rare without evidence of hepatotoxicity, and it usually presents with confusion, agitation, irritability, cognitive disturbances, lethargy, coma, and death." | 1.48 | Valproate-induced Hyperammonemic Encephalopathy Presenting as Catatonia. ( Espínola-Nadurille, M; Oñate-Cadena, N; Pérez-Esparza, R; Ramírez-Bermúdez, J, 2018) |
| "Specific treatment for hyperammonemia must be implemented promptly." | 1.48 | Valproate-induced hyperammonemia - uncovering an underlying inherited metabolic disorder: a case report. ( Lachmann, R; Mehta, S; Tayabali, S, 2018) |
| "Carnitine is a commonly used antidote for acute intoxication of valproic acid, but is not a therapeutic option for management of chronic adults with adverse effects related to valproic acid." | 1.46 | L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report. ( Fagiolino, P; Guevara, N; Maldonado, C; Silveira, A; Vázquez, M, 2017) |
| "We report five adult patients with frontal lobe epilepsy (FLE) who were treated with VPA and in whom a primary adverse effect was unstable gait and falls." | 1.46 | Gait instability in valproate-treated patients: Call to measure ammonia levels. ( Elger, CE; Kipervasser, S; Korczyn, AD; Nass, RD; Neufeld, MY; Quesada, CM, 2017) |
| "Valproic acid (VPA) has been associated with coagulation factors deficiency, platelet dysfunction and hemorrhagic complications." | 1.43 | Valproic acid as an antiepileptic drug: Is there a clinical relevance for the epilepsy surgeon? ( Arora, A; Chandra, PS; Garg, K; Kurwale, N; Tripathi, M, 2016) |
| "Carnitine supplement was administrated in two patients, which resulted in resolution of symptoms and normalized ammonium levels." | 1.40 | Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease). ( Larsen, EP; Ostergaard, JR, 2014) |
| "Valproate-induced hyperammonemic encephalopathy is an uncommon but serious effect of valproate treatment." | 1.40 | Valproate-induced hyperammonemic encephalopathy in a renal transplanted patient. ( Boletis, JN; Darema, M; Efthimiou, A; Marinaki, S; Melexopoulou, C; Skalioti, C; Zavos, G, 2014) |
| "Hyperammonemia was defined as a plasma ammonia level exceeding 100 μg/dl with reference to the standard range and previous reports." | 1.39 | Risk factors for hyperammonemia in pediatric patients with epilepsy. ( Imai, K; Inoue, K; Inoue, Y; Itoh, K; Kagawa, Y; Mishima, N; Takahashi, Y; Yamamoto, Y; Yazawa, R, 2013) |
| "We present a case of hyperammonaemic coma precipitated by sodium valproate use for symptomatic epilepsy in a patient with unrecognised portosystemic shunt, secondary to earlier alcoholism." | 1.39 | Valproic acid-induced hyperammonaemic coma and unrecognised portosystemic shunt. ( Basilio, C; Carrapatoso, L; Ferreira, F; Nzwalo, H, 2013) |
| " In many situations, the final choice of an antiepileptic drug may need a change due to the agent's side-effect profile." | 1.37 | Cerebellar atrophy in a child with valproate toxicity. ( Bhatt, S; Ghosh, VB; Kapoor, S; Prakash, A, 2011) |
| "Hyperammonemia was detected in 8 patients treated with valproic acid." | 1.36 | Serum biotinidase activity in children treated with valproic acid and carbamazepine. ( Castiñeiras-Ramos, DE; Castro-Gago, M; Díaz-Mayo, I; Eirís-Puñal, J; Gómez-Lado, C, 2010) |
| "Valproate-induced hyperammonemic encephalopathy is an unusual but serious complication that may occur in people with normal liver-associated enzyme levels, despite normal therapeutic doses and serum levels of valproate." | 1.35 | Valproate-induced hyperammonemic encephalopathy treated by hemodialysis. ( Chen, CY; Tsai, MF, 2008) |
| "Transient hyperammonemia was noted." | 1.35 | Postictal transient hyperammonemia. ( Liu, KT; Su, CS, 2008) |
| "To describe the dose-concentration relationship of a continuous intravenous infusion of valproic acid (VPA) in pediatric patients when a dosing protocol is used." | 1.34 | Clinical utility of a continuous intravenous infusion of valproic acid in pediatric patients. ( Baumann, RJ; Cook, AM; Farzam, F; Kuhn, RJ; Lewis, DA; Taylor, LM, 2007) |
| "This drug-associated encephalopathy is a reversible but potentially fatal cause, probably underdiagnosed, that requires a high index of suspicion." | 1.34 | [Valproate-associated hyperammonemic encephalopathy. Report of one case]. ( Alvarez, F; Bruetman, JE; Finn, BC; Trimarchi, H; Young, P, 2007) |
| "Valproic acid-associated hyperammonemic encephalopathy (VHE) has been described in the neurology and emergency medicine literature, but the case reports identified therein are rarely derived from the psychiatric use of this medication." | 1.33 | Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric setting. ( Irwin, SA; Kimmel, RJ; Meyer, JM, 2005) |
| "A 56-year-old woman with poorly controlled epilepsy, receiving valproate at subtherapeutic levels for 6 years, developed a life-threatening hyperammonemic coma following a moderate dosage increase." | 1.33 | Acute hyperammonemic coma with chronic valproic acid therapy. ( Abramson, RK; Cuturic, M, 2005) |
| "Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated." | 1.33 | Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children. ( Augspach-Hofmann, R; Bendl, C; Buesing, D; Fitzek, S; Gerstner, T; Goetze, G; Haensch, CA; Klostermann, W; Koenig, SA; Lippert, G; Longin, E; Macke, A; Mayer, G; Reuland, M; Scheid, B; Wenzel, D, 2006) |
| "Valproic acid was discontinued which resulted in rapid clinical recovery." | 1.32 | Ammonia induced encephalopathy from valproic acid in a bipolar patient: case report. ( Elgudin, L; Hall, Y; Schubert, D, 2003) |
| "Acute hyperammonemia is a medical emergency for which immediate steps must be taken to minimize permanent brain damage." | 1.32 | Unusual causes of hyperammonemia in the ED. ( Chen, WJ; Shih, FF; Weng, TI, 2004) |
| "VPA-induced hyperammonemic encephalopathy in adults is a rare phenomenon, especially when VPA is used as monotherapy." | 1.32 | Hyperammonemic encephalopathy induced by a combination of valproate and pivmecillinam. ( Asztely, F; Eriksson, B; Lokrantz, CM; Rosén, I, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 60 (32.97) | 29.6817 |
| 2010's | 93 (51.10) | 24.3611 |
| 2020's | 29 (15.93) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L | 2 |
| Xu, Z | 2 |
| Huang, H | 1 |
| Nicholson, C | 1 |
| Fowler, M | 1 |
| Mullen, C | 1 |
| Cunningham, B | 1 |
| De Fazio, C | 1 |
| Goffin, M | 1 |
| Franchi, F | 1 |
| Ferlini, L | 1 |
| Orinckx, C | 1 |
| Spadaro, S | 1 |
| Brasseur, A | 1 |
| Gaspard, N | 1 |
| Antonucci, E | 1 |
| Khattar, L | 1 |
| Peluso, L | 1 |
| Romeo, I | 1 |
| Creteur, J | 1 |
| Legros, B | 1 |
| Taccone, FS | 1 |
| Young, MR | 1 |
| Bisaccia, EK | 1 |
| Romantseva, L | 1 |
| Hovey, SW | 1 |
| Anthonipillai, P | 1 |
| Sharp, G | 1 |
| Kimber, J | 1 |
| Ziauddin, V | 1 |
| Chen, Y | 1 |
| Chen, J | 1 |
| Zhuang, X | 1 |
| Chen, X | 1 |
| Zeng, J | 1 |
| Wang, R | 2 |
| Miao, J | 1 |
| Vakrinou, A | 1 |
| Murphy, E | 1 |
| Sisodiya, SM | 1 |
| Vivekananda, U | 1 |
| Balestrini, S | 1 |
| Szczygieł-Pilut, EE | 1 |
| Zajączkowska-Dutkiewicz, A | 1 |
| Pilut, D | 1 |
| Dutkiewicz, J | 1 |
| Patel, J | 1 |
| Berezowski, I | 1 |
| Mazer-Amirshahi, M | 1 |
| Frasure, SE | 1 |
| Tran, QK | 1 |
| Pourmand, A | 1 |
| Hosseini, H | 3 |
| Shafie, M | 3 |
| Shakiba, A | 3 |
| Ghayyem, H | 3 |
| Mayeli, M | 3 |
| Hassani, M | 3 |
| Aghamollaii, V | 3 |
| van Haaren, PCF | 1 |
| Bloemkolk, D | 1 |
| Rundervoort, RS | 1 |
| Gerritse, FL | 1 |
| Schiavo, A | 1 |
| Maldonado, C | 3 |
| Vázquez, M | 3 |
| Fagiolino, P | 3 |
| Trocóniz, IF | 1 |
| Ibarra, M | 2 |
| Shakerdi, L | 1 |
| Ryan, A | 1 |
| Pavuluri, H | 1 |
| Jose, M | 1 |
| Fasaludeen, A | 1 |
| Sundaram, S | 1 |
| Radhakrishnan, A | 1 |
| Banerjee, M | 1 |
| Menon, RN | 1 |
| Liu, X | 1 |
| Peng, X | 1 |
| Sharma, DS | 1 |
| Gupta, S | 1 |
| Sharma, P | 1 |
| Loser, V | 1 |
| Novy, J | 1 |
| Beuchat, I | 1 |
| Rossetti, AO | 2 |
| McCarron, EP | 1 |
| Kwack, DW | 1 |
| Kim, DW | 1 |
| Ranjith, S | 1 |
| Abeysundera, H | 1 |
| Jeyaranjan, H | 1 |
| Pliego Cosano, R | 1 |
| Moreno Rosauro, JM | 1 |
| Clavero Olmos, M | 1 |
| Baumgartner, J | 1 |
| Hoeflich, A | 1 |
| Hinterbuchinger, B | 1 |
| Fellinger, M | 1 |
| Graf, I | 1 |
| Friedrich, F | 1 |
| Frey, R | 1 |
| Mossaheb, N | 1 |
| Khakwani, A | 1 |
| Gannon, D | 1 |
| Shah, S | 1 |
| Vieux, U | 1 |
| Ilieva, HS | 1 |
| Newman, JW | 1 |
| Fields, RK | 1 |
| Croom, JE | 1 |
| Habhab, SF | 1 |
| Ulvin, LB | 1 |
| Taubøll, E | 1 |
| Svalheim, S | 1 |
| Olsen, KB | 1 |
| Horn, MA | 1 |
| Heuser, K | 1 |
| Woo, PYM | 1 |
| Woo, AWY | 1 |
| Lam, SW | 1 |
| Ko, NMW | 1 |
| Ho, JWK | 1 |
| Chu, ACH | 1 |
| Kwan, MCL | 1 |
| Chan, Y | 1 |
| Wong, HT | 1 |
| Chan, KY | 1 |
| Pagali, S | 1 |
| Edquist, C | 1 |
| O'Rourke, N | 1 |
| Smith, KM | 1 |
| Britton, JW | 1 |
| Hocker, SE | 1 |
| Toledano, M | 1 |
| Wu, J | 1 |
| Li, J | 1 |
| Jing, W | 1 |
| Tian, X | 2 |
| Wang, X | 1 |
| Kazmierski, D | 1 |
| Sharma, N | 1 |
| O'Leary, K | 1 |
| Ochieng, P | 1 |
| Beddoes, P | 1 |
| Nerone, G | 1 |
| Tai, C | 1 |
| Guo, X | 1 |
| Wei, J | 1 |
| Gao, L | 1 |
| Xing, B | 1 |
| Guevara, N | 2 |
| Silveira, A | 1 |
| Kipervasser, S | 1 |
| Elger, CE | 1 |
| Korczyn, AD | 1 |
| Nass, RD | 1 |
| Quesada, CM | 1 |
| Neufeld, MY | 1 |
| Cherian, KA | 1 |
| Legatt, AD | 1 |
| Cattaneo, CI | 1 |
| Ressico, F | 1 |
| Valsesia, R | 1 |
| D'Innella, P | 1 |
| Ballabio, M | 1 |
| Fornaro, M | 1 |
| Suzuki, H | 1 |
| Hibino, H | 1 |
| Inoue, Y | 6 |
| Mikami, A | 1 |
| Matsumoto, H | 1 |
| Mikami, K | 1 |
| Diaz-Rangel, M | 1 |
| Grande-Martin, A | 1 |
| Monsalve-Naharro, JA | 1 |
| Domingo-Chiva, E | 1 |
| Cuesta-Montero, P | 1 |
| Lopez-Perez, A | 1 |
| Pérez-Esparza, R | 1 |
| Oñate-Cadena, N | 1 |
| Ramírez-Bermúdez, J | 1 |
| Espínola-Nadurille, M | 1 |
| Triplett, KE | 1 |
| Murray, R | 1 |
| Anstey, M | 1 |
| Mehta, S | 1 |
| Tayabali, S | 1 |
| Lachmann, R | 1 |
| Zhu, X | 1 |
| Li, X | 1 |
| Zhang, T | 1 |
| Zhao, L | 1 |
| Camilleri, L | 1 |
| Izadi Firouzabadi, L | 1 |
| Geer, K | 1 |
| Mead, P | 1 |
| Baudou, E | 1 |
| Benevent, J | 1 |
| Montastruc, JL | 1 |
| Touati, G | 1 |
| Hachon LeCamus, C | 1 |
| Lind, J | 1 |
| Nordlund, P | 1 |
| Yamada, H | 1 |
| Shishido, T | 1 |
| Mukai, T | 1 |
| Araki, M | 1 |
| Naka, H | 1 |
| Tokinobu, H | 1 |
| Tian, Q | 1 |
| Zhang, M | 1 |
| Chen, D | 1 |
| Gao, X | 1 |
| Yang, H | 1 |
| Li, H | 1 |
| Li, C | 1 |
| Wen, J | 1 |
| Li, Y | 1 |
| Chen, P | 1 |
| Yamamoto, Y | 5 |
| Takahashi, Y | 5 |
| Imai, K | 4 |
| Mishima, N | 3 |
| Yazawa, R | 2 |
| Inoue, K | 4 |
| Itoh, K | 4 |
| Kagawa, Y | 3 |
| Jones, GL | 1 |
| Popli, GS | 1 |
| Silvia, MT | 1 |
| Lucie, O | 1 |
| Nazir, F | 1 |
| Spilg, E | 1 |
| Belze, O | 1 |
| Remérand, F | 1 |
| Pujol, A | 1 |
| Fusciardi, J | 1 |
| Nzwalo, H | 1 |
| Carrapatoso, L | 1 |
| Ferreira, F | 1 |
| Basilio, C | 1 |
| Nanau, RM | 1 |
| Neuman, MG | 1 |
| Amanat, S | 1 |
| Shahbaz, N | 1 |
| Hassan, Y | 1 |
| Halaby, A | 1 |
| Haddad, R | 1 |
| Naja, WJ | 1 |
| Sarlon, J | 1 |
| Hess, E | 1 |
| Krasnianski, A | 1 |
| Rigamonti, A | 1 |
| Lauria, G | 1 |
| Grimod, G | 1 |
| Bianchi, G | 1 |
| Salmaggi, A | 1 |
| Santos-Cubiñá, J | 1 |
| Torres-Rodríguez, A | 1 |
| Castaing-Lespier, PA | 1 |
| Sabaté, N | 1 |
| Torres-Martin, A | 1 |
| Carlo, S | 1 |
| Fernández Colomer, B | 1 |
| Rekarte García, S | 1 |
| García López, JE | 1 |
| Pérez González, C | 1 |
| Montes Granda, M | 1 |
| Coto Cotallo, GD | 1 |
| Selvi, Y | 1 |
| Annagur, BB | 1 |
| Sayin, AA | 1 |
| Akbaba, N | 1 |
| Larsen, EP | 1 |
| Ostergaard, JR | 1 |
| Melexopoulou, C | 1 |
| Marinaki, S | 1 |
| Darema, M | 1 |
| Skalioti, C | 1 |
| Efthimiou, A | 1 |
| Zavos, G | 1 |
| Boletis, JN | 1 |
| Pegg, EJ | 1 |
| Zaman, F | 1 |
| Olmos, I | 1 |
| Alvariza, S | 1 |
| Magallanes, L | 1 |
| Olano, I | 1 |
| Suzuki, E | 3 |
| Takahashi, T | 2 |
| Miyakawa, K | 1 |
| Tsuji, D | 2 |
| Hayashi, H | 1 |
| Kowalski, PC | 1 |
| Dowben, JS | 1 |
| Keltner, NL | 1 |
| Tseng, YL | 1 |
| Huang, CR | 1 |
| Lin, CH | 1 |
| Lu, YT | 1 |
| Lu, CH | 1 |
| Chen, NC | 1 |
| Chang, CC | 1 |
| Chang, WN | 1 |
| Chuang, YC | 1 |
| Villalba Martínez, G | 1 |
| Fernández-Candil, JL | 1 |
| Vivanco-Hidalgo, RM | 1 |
| Pacreu Terradas, S | 1 |
| León Jorba, A | 1 |
| Arroyo Pérez, R | 1 |
| Fukuda, M | 1 |
| Kawabe, M | 1 |
| Takehara, M | 1 |
| Iwano, S | 1 |
| Kuwabara, K | 1 |
| Kikuchi, C | 1 |
| Wakamoto, H | 1 |
| Morimoto, T | 1 |
| Suzuki, Y | 1 |
| Ishii, E | 1 |
| Sencion Martinez, GL | 1 |
| Samillán, K | 1 |
| Espinosa, JL | 1 |
| Rodriguez Puyol, D | 1 |
| Martinez Miguel, P | 1 |
| Villa, P | 1 |
| Shah, UA | 1 |
| Henderson, MC | 1 |
| Abourjaily, P | 1 |
| Thaler, D | 1 |
| Rencic, J | 1 |
| Walker, V | 1 |
| Al-sharefi, A | 1 |
| Bilous, R | 1 |
| Hirai, K | 1 |
| Thomas, KL | 1 |
| La, AQ | 1 |
| Punia, S | 1 |
| Doroudgar, S | 1 |
| Perry, PJ | 1 |
| Dawson, LP | 1 |
| Lee, SJ | 1 |
| Hollander, YS | 1 |
| Hirose, T | 1 |
| Ciftci, S | 1 |
| Guler, A | 1 |
| Deveci, E | 1 |
| Celebisoy, N | 1 |
| Yuceyar, N | 1 |
| Monostory, K | 1 |
| Bűdi, T | 1 |
| Tóth, K | 1 |
| Nagy, A | 1 |
| Szever, Z | 1 |
| Kiss, Á | 1 |
| Temesvári, M | 1 |
| Háfra, E | 1 |
| Tapodi, A | 1 |
| Garami, M | 1 |
| Kurwale, N | 1 |
| Garg, K | 1 |
| Arora, A | 1 |
| Chandra, PS | 1 |
| Tripathi, M | 1 |
| Lin, MW | 1 |
| Chang, C | 1 |
| Yeh, CB | 1 |
| Tai, YM | 1 |
| Chang, HA | 1 |
| Kao, YC | 1 |
| Tzeng, NS | 1 |
| Gandolfo, F | 1 |
| Parodi, MN | 1 |
| Corsini, GP | 1 |
| Odetti, P | 1 |
| Serafini, G | 1 |
| Monacelli, F | 1 |
| Patel, N | 1 |
| Landry, KB | 1 |
| Fargason, RE | 1 |
| Birur, B | 1 |
| Schrettl, V | 1 |
| Felgenhauer, N | 2 |
| Rabe, C | 1 |
| Fernando, M | 1 |
| Eyer, F | 2 |
| Pokorná, P | 1 |
| Hronová, K | 1 |
| Šíma, M | 1 |
| Slanař, O | 1 |
| Klement, P | 1 |
| van den Anker, JN | 1 |
| Tibboel, D | 1 |
| Fan, CC | 1 |
| Huang, MC | 1 |
| Liu, HC | 1 |
| Tsai, MF | 1 |
| Chen, CY | 1 |
| Mehndiratta, MM | 1 |
| Mehndiratta, P | 1 |
| Phul, P | 1 |
| Garg, S | 1 |
| Berlot, G | 1 |
| Battaglia, K | 1 |
| Ukmar, M | 1 |
| Garcia, M | 1 |
| Huppertz, HJ | 1 |
| Ziyeh, S | 2 |
| Buechert, M | 1 |
| Schumacher, M | 2 |
| Mader, I | 1 |
| Lheureux, PE | 2 |
| Hantson, P | 1 |
| DeWolfe, JL | 1 |
| Knowlton, RC | 1 |
| Beasley, MT | 1 |
| Cofield, S | 1 |
| Faught, E | 1 |
| Limdi, NA | 1 |
| Shan, JC | 1 |
| Hsieh, MH | 1 |
| Liu, CC | 1 |
| Wen, CC | 1 |
| Liu, CM | 1 |
| Abreu, LN | 1 |
| Issler, C | 1 |
| Lafer, B | 1 |
| Hamed, SA | 1 |
| Abdella, MM | 1 |
| Castro-Gago, M | 1 |
| Gómez-Lado, C | 1 |
| Eirís-Puñal, J | 1 |
| Díaz-Mayo, I | 1 |
| Castiñeiras-Ramos, DE | 1 |
| Rousseau, MC | 1 |
| Montana, M | 1 |
| Villano, P | 1 |
| Catala, A | 1 |
| Blaya, J | 1 |
| Valkov, M | 1 |
| Allouard, Y | 1 |
| Bugni, E | 1 |
| Cottle, D | 1 |
| Dean, P | 1 |
| Khoo, CL | 1 |
| Naik, S | 1 |
| Lua, R | 1 |
| Chai, SB | 1 |
| Liew, A | 1 |
| Sim, K | 1 |
| Starer, J | 1 |
| Chang, G | 1 |
| Yagi, M | 1 |
| Nakamura, T | 1 |
| Okizuka, Y | 1 |
| Oyazato, Y | 1 |
| Kawasaki, Y | 1 |
| Tsuneishi, S | 1 |
| Sakaeda, T | 1 |
| Matsuo, M | 1 |
| Okumura, K | 1 |
| Okamura, N | 1 |
| Granel, B | 1 |
| Gavaret, M | 1 |
| Le Baut, X | 1 |
| Sautereau, N | 1 |
| Rodriguez, D | 1 |
| Rossi, P | 1 |
| Bagnères, D | 1 |
| Demoux, AL | 1 |
| Francès, Y | 1 |
| LaBuzetta, JN | 1 |
| Yao, JZ | 1 |
| Bourque, DL | 1 |
| Zivin, J | 1 |
| Dichtwald, S | 1 |
| Dahan, E | 1 |
| Adi, N | 1 |
| Moses, A | 1 |
| Sorkine, P | 1 |
| Weissbach, A | 1 |
| Tirosh, I | 1 |
| Scheuerman, O | 1 |
| Hoffer, V | 1 |
| Garty, BZ | 1 |
| Young, L | 1 |
| Coffey, BJ | 1 |
| de las Heras, J | 1 |
| Garin, I | 1 |
| de Nanclares, GP | 1 |
| Aguayo, A | 1 |
| Rica, I | 1 |
| Castaño, L | 1 |
| Vela, A | 1 |
| Aires, CC | 1 |
| van Cruchten, A | 1 |
| Ijlst, L | 1 |
| de Almeida, IT | 1 |
| Duran, M | 1 |
| Wanders, RJ | 1 |
| Silva, MF | 1 |
| Ghosh, VB | 1 |
| Kapoor, S | 1 |
| Prakash, A | 1 |
| Bhatt, S | 1 |
| Scarano, V | 1 |
| Bellarosa, I | 1 |
| Bertogliatti, S | 1 |
| Terracciano, AM | 1 |
| Orlando, V | 1 |
| Gomez-Ibañez, A | 1 |
| Urrestarazu-Bolumburu, E | 1 |
| Viteri-Torres, C | 1 |
| Bezinover, D | 1 |
| Postula, M | 1 |
| Donahue, K | 1 |
| Bentzen, B | 1 |
| McInerney, J | 1 |
| Janicki, PK | 1 |
| Davison, AS | 1 |
| Milan, AM | 1 |
| Roberts, NB | 1 |
| Sonik, P | 1 |
| Hilty, DM | 1 |
| Rossaro, L | 1 |
| Bourgeois, JA | 2 |
| Sano, A | 1 |
| Prins, MC | 1 |
| van Meijel, JJ | 1 |
| Garg, R | 1 |
| Sunder, RA | 1 |
| Joardar, S | 1 |
| Das, S | 1 |
| Chatterjee, R | 1 |
| Guha, G | 1 |
| Hasmi, MA | 1 |
| Mock, CM | 1 |
| Schwetschenau, KH | 1 |
| Bocchetta, A | 1 |
| Siddu, A | 1 |
| Sardu, C | 1 |
| Sarnicola, A | 1 |
| Martinelli, V | 1 |
| Grynnerup, A | 1 |
| Fernández, IS | 1 |
| Hernández, JC | 1 |
| Martínez, AD | 1 |
| López, JM | 1 |
| García-Alix, A | 1 |
| Lewis, C | 1 |
| Deshpande, A | 1 |
| Tesar, GE | 1 |
| Dale, R | 1 |
| Hong, L | 1 |
| Schutz, J | 1 |
| Nance, M | 1 |
| Martín-del Rincón, JP | 1 |
| Llompart-Pou, JA | 1 |
| Ferreruela, M | 1 |
| Velasco, J | 1 |
| Holroyd, S | 1 |
| Overdyke, JT | 1 |
| Kesav, P | 1 |
| V Y, V | 1 |
| Khurana, D | 1 |
| Cheng, M | 1 |
| Tang, X | 1 |
| Wen, S | 1 |
| Yue, J | 1 |
| Wang, H | 1 |
| Chan, E | 1 |
| McQueen, F | 1 |
| O'Neill, M | 1 |
| Dubrey, RW | 1 |
| Grocott-Mason, RM | 1 |
| Thiel, T | 1 |
| Spreer, J | 1 |
| Klisch, J | 1 |
| Raja, M | 1 |
| Azzoni, A | 1 |
| Murphy, JV | 1 |
| Verrotti, A | 1 |
| Trotta, D | 1 |
| Morgese, G | 1 |
| Chiarelli, F | 1 |
| Elgudin, L | 1 |
| Hall, Y | 1 |
| Schubert, D | 1 |
| Weng, TI | 1 |
| Shih, FF | 1 |
| Chen, WJ | 1 |
| Lokrantz, CM | 1 |
| Eriksson, B | 1 |
| Rosén, I | 1 |
| Asztely, F | 1 |
| Yehya, N | 1 |
| Saldarini, CT | 1 |
| Koski, ME | 1 |
| Davanzo, P | 1 |
| Mallet, L | 1 |
| Babin, S | 1 |
| Morais, JA | 1 |
| McCall, M | 1 |
| Nakazato, Y | 1 |
| Ando, S | 1 |
| Yamamoto, T | 1 |
| Tamura, N | 1 |
| Shimazu, K | 1 |
| Kimmel, RJ | 1 |
| Irwin, SA | 1 |
| Meyer, JM | 1 |
| Fukushima, M | 1 |
| Kotoh, K | 1 |
| Enjoji, M | 1 |
| Nakamuta, M | 1 |
| Nawata, H | 1 |
| Aishima, S | 1 |
| Cheung, E | 1 |
| Wong, V | 1 |
| Fung, CW | 1 |
| Panda, S | 1 |
| Radhakrishnan, K | 1 |
| Bhatia, H | 1 |
| Raman, PG | 1 |
| Stewart, JT | 2 |
| Shibata, A | 1 |
| Hayashi, S | 1 |
| Noguchi, M | 1 |
| Gempel, K | 1 |
| Steimer, W | 1 |
| Gerbitz, KD | 1 |
| Zilker, T | 1 |
| Bromfield, EB | 1 |
| Turcato, Mde F | 1 |
| Fernandes, RM | 1 |
| Wichert-Ana, L | 1 |
| Funayama, CA | 1 |
| Penaloza, A | 1 |
| Zahir, S | 1 |
| Gris, M | 1 |
| Cuturic, M | 1 |
| Abramson, RK | 1 |
| Thakur, V | 1 |
| Rupar, CA | 1 |
| Ramsay, DA | 1 |
| Singh, R | 1 |
| Fraser, DD | 1 |
| Segura-Bruna, N | 1 |
| Rodriguez-Campello, A | 1 |
| Puente, V | 1 |
| Roquer, J | 1 |
| Gerstner, T | 1 |
| Buesing, D | 1 |
| Longin, E | 2 |
| Bendl, C | 1 |
| Wenzel, D | 1 |
| Scheid, B | 1 |
| Goetze, G | 1 |
| Macke, A | 1 |
| Lippert, G | 1 |
| Klostermann, W | 1 |
| Mayer, G | 1 |
| Augspach-Hofmann, R | 1 |
| Fitzek, S | 1 |
| Haensch, CA | 1 |
| Reuland, M | 1 |
| Koenig, SA | 1 |
| Soares-Fernandes, JP | 1 |
| Machado, A | 1 |
| Ribeiro, M | 1 |
| Ferreira, C | 1 |
| Figueiredo, J | 1 |
| Rocha, JF | 1 |
| Guaiana, G | 1 |
| Eyrek, C | 1 |
| Mariconda, G | 1 |
| Carlson, T | 1 |
| Reynolds, CA | 1 |
| Caplan, R | 1 |
| Taylor, LM | 1 |
| Farzam, F | 1 |
| Cook, AM | 1 |
| Lewis, DA | 1 |
| Baumann, RJ | 1 |
| Kuhn, RJ | 1 |
| Gomceli, YB | 1 |
| Kutlu, G | 1 |
| Cavdar, L | 1 |
| Sanivar, F | 1 |
| Inan, LE | 1 |
| Nicolai, J | 2 |
| Aldenkamp, AP | 1 |
| Huizenga, JR | 1 |
| Teune, LK | 1 |
| Brouwer, OF | 1 |
| Carr, RB | 1 |
| Shrewsbury, K | 1 |
| Velioğlu, SK | 1 |
| Gazioğlu, S | 1 |
| Dealberto, MJ | 1 |
| Modjtahedi, B | 1 |
| Xiong, GL | 1 |
| Young, P | 1 |
| Finn, BC | 1 |
| Alvarez, F | 1 |
| Bruetman, JE | 1 |
| Trimarchi, H | 1 |
| Meinardi, MC | 1 |
| van den Berg, GB | 1 |
| Groenhuijzen, A | 1 |
| Driessen, JT | 1 |
| Maas, HA | 1 |
| Wolfhagen, FH | 1 |
| Liu, KT | 1 |
| Su, CS | 1 |
| Chan, YC | 1 |
| Tse, ML | 1 |
| Lau, FL | 1 |
| Dumont, O | 1 |
| Plauchu, G | 1 |
| Scoazec, JY | 1 |
| Cuber, JC | 1 |
| Guegen, L | 1 |
| Paliard, P | 1 |
| Dumortier, J | 1 |
| Smith, SJ | 1 |
| Keunen, RW | 1 |
| Barrueto, F | 1 |
| Hack, JB | 1 |
| Padilla, Mde L | 1 |
| Miguélez, M | 1 |
| Riverola, A | 1 |
| Bueno, J | 1 |
| Vossler, DG | 1 |
| Wilensky, AJ | 1 |
| Cawthon, DF | 1 |
| Kraemer, DL | 1 |
| Ojemann, LM | 1 |
| Caylor, LM | 1 |
| Morgan, JD | 1 |
| Teich, M | 1 |
| Koelfen, W | 1 |
| König, S | 1 |
| Schwarz, S | 1 |
| Georgiadis, D | 1 |
| Schwab, S | 1 |
| Gehlen, F | 1 |
| Mayatepek, E | 1 |
| Zoubaa, S | 1 |
| Vainstein, G | 1 |
| Korzets, Z | 1 |
| Pomeranz, A | 1 |
| Gadot, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PSG in Valproate-induced Nocturnal Enuresis in Children[NCT04191863] | 260 participants (Actual) | Observational | 2018-09-01 | Completed | |||
| Effect of Adding Lamotrigine to Sodium Valproate in Childhood Epilepsy: Clinicolabratory Study[NCT05881928] | Phase 4 | 50 participants (Anticipated) | Interventional | 2023-07-25 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
29 reviews available for valproic acid and Hyperammonemia
| Article | Year |
|---|---|
Risk factors and outcome of hyperammonaemia in people with epilepsy.
Topics: Adult; Ammonia; Epilepsy; Humans; Hyperammonemia; Observational Studies as Topic; Oxcarbazepine; Ris | 2022 |
Valproic Acid Overdose: Case Report and Literature Review.
Topics: Anticonvulsants; Carnitine; Drug Overdose; Humans; Hyperammonemia; Male; Middle Aged; Valproic Acid | 2022 |
Drug-induced hyperammonaemia.
Topics: Ammonia; Brain; Child; Humans; Hyperammonemia; Valproic Acid | 2023 |
Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy.
Topics: Adult; Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Risk Factors; Topiramate; Valproi | 2023 |
L-carnitine supplementation as a potential therapy for suspected hyperammonaemic encephalopathy.
Topics: Adult; Anticonvulsants; Blood Chemical Analysis; Carnitine; Cerebral Palsy; Dietary Supplements; Epi | 2019 |
Valproic acid-induced encephalopathy: A review of clinical features, risk factors, diagnosis, and treatment.
Topics: Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Risk Factors; Valproic Acid | 2021 |
Hyperammonemic coma after craniotomy: Hepatic encephalopathy from upper gastrointestinal hemorrhage or valproate side effect?: Case report and literature review.
Topics: Anticonvulsants; Coma; Craniotomy; Diagnosis, Differential; Female; Gastrointestinal Hemorrhage; Hep | 2017 |
Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Carnitine; Humans; Hyperammonemia; Male; Substance-Relate | 2017 |
Lesson of the month 1: Sodium valproate-induced encephalopathy.
Topics: Aged; Ammonia; Anticonvulsants; Brain Diseases; Carnitine; Consciousness Disorders; Epilepsy; Humans | 2018 |
[Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
Topics: Aged; Ammonia; Anticonvulsants; Biomarkers; Cardiomyopathies; Carnitine; Consciousness Disorders; Ep | 2019 |
CPS1 T1405N polymorphism, HDL cholesterol, homocysteine and renal function are risk factors of VPA induced hyperammonemia among epilepsy patients.
Topics: Anticonvulsants; Carbamoyl-Phosphate Synthase (Ammonia); Case-Control Studies; Cholesterol, HDL; Epi | 2019 |
Adverse drug reactions induced by valproic acid.
Topics: Anticonvulsants; Antipsychotic Agents; Drug Hypersensitivity; Endocrine System; Epilepsy; Humans; Hy | 2013 |
Valproate induced hyperammonemic encephalopathy successfully treated with levocarnitine.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Diagnosis, Differential; Humans; Hyperammonemia; Male; Neur | 2014 |
Ammonia metabolism and hyperammonemic disorders.
Topics: Ammonia; Animals; Arginine; Biological Transport; Brain; Cell Membrane; Humans; Hyperammonemia; Hype | 2014 |
Valproic acid-induced hyperammonemic encephalopathy in a full-term neonate: a brief review and case report.
Topics: Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Infant, Newborn; Seizures; Valproic Acid | 2017 |
Carnitine in the treatment of valproic acid-induced toxicity.
Topics: Animals; Anticonvulsants; Antidotes; Carnitine; Chemical and Drug Induced Liver Injury; Energy Metab | 2009 |
Valproate-induced hyperammonemia in mental retardation: a case report and review of the literature.
Topics: Adult; Antimanic Agents; Female; Humans; Hyperammonemia; Mental Disorders; Valproic Acid | 2010 |
Adult nonhepatic hyperammonemia: a case report and differential diagnosis.
Topics: Ammonia; Diagnosis, Differential; Humans; Hyperammonemia; Liver Diseases; Male; Metabolism, Inborn E | 2010 |
[Pharmacogenetics focused on special phenotypes].
Topics: Antipsychotic Agents; Humans; Hyperammonemia; Malignant Hyperthermia; Mutation; Parkinsonian Disorde | 2011 |
Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy.
Topics: Carnitine; Humans; Hyperammonemia; Neurotoxicity Syndromes; Valproic Acid | 2012 |
Valproate-induced hyperammonemic encephalopathy: a brief review.
Topics: Adult; Anticonvulsants; Child; Hepatic Encephalopathy; Humans; Hyperammonemia; Models, Biological; N | 2012 |
Valproate-induced hyperammonaemia superimposed upon severe neuropsychiatric lupus: a case report and review of the literature.
Topics: Ammonia; Antimanic Agents; Fatal Outcome; Female; Humans; Hyperammonemia; Lupus Vasculitis, Central | 2013 |
Valproate-induced hyperammonemic encephalopathy.
Topics: Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Valproic Acid | 2002 |
[A case of valproate-associated hyperammonemia with chronic hepatitis C].
Topics: Anticonvulsants; Epilepsy; Hepatitis C, Chronic; Humans; Hyperammonemia; Male; Middle Aged; Valproic | 2005 |
[Successful balloon-occluded retrograde transvenous obliteration (B-RTO) in a case of symptomatic epilepsy with hepatic encephalopathy due to non-cirrhotic porto-systemic shunt].
Topics: Aged; Anticonvulsants; Balloon Occlusion; Epilepsy; Hepatic Encephalopathy; Humans; Hyperammonemia; | 2005 |
Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?
Topics: Anticonvulsants; Carnitine; Chemical and Drug Induced Liver Injury; Drug Overdose; Hepatic Encephalo | 2005 |
Valproate-induced hyperammonemic encephalopathy.
Topics: Anticonvulsants; Brain; Brain Edema; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Carnitine | 2006 |
Hyperammonemia due to valproic acid in the psychiatric setting.
Topics: Adult; Aged; Bipolar Disorder; Carnitine; Child; Female; Humans; Hyperammonemia; Liver; Middle Aged; | 2007 |
Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting.
Topics: Antimanic Agents; Hospitals, Psychiatric; Humans; Hyperammonemia; Neurotoxicity Syndromes; Valproic | 2007 |
3 trials available for valproic acid and Hyperammonemia
| Article | Year |
|---|---|
Hyperammonemia following intravenous valproate loading.
Topics: Adult; Aged; Ammonia; Analysis of Variance; Anticonvulsants; Bilirubin; Dose-Response Relationship, | 2009 |
The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
Topics: Adolescent; Ammonia; Anticonvulsants; Carnitine; Child; Epilepsy; Female; Humans; Hyperammonemia; Ma | 2009 |
Cognitive side effects of valproic acid-induced hyperammonemia in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Cognition Disorders; Epilepsy; Female; Humans; Hyperammonemia; M | 2007 |
150 other studies available for valproic acid and Hyperammonemia
| Article | Year |
|---|---|
Non-hyperammonaemia valproate-induced encephalopathy: A case report.
Topics: Anticonvulsants; Brain Diseases; Epilepsy; Female; Humans; Hyperammonemia; Middle Aged; Valproic Aci | 2022 |
Evaluation of levocarnitine, lactulose, and combination therapy for the treatment of valproic acid-induced hyperammonemia in critically ill patients.
Topics: Carnitine; Cohort Studies; Critical Illness; Humans; Hyperammonemia; Lactulose; Retrospective Studie | 2021 |
Hyperammonemia during treatment with valproate in critically ill patients.
Topics: Aged; Critical Care; Critical Illness; Enzyme Inhibitors; Female; Humans; Hyperammonemia; Incidence; | 2022 |
Valproic Acid Serum Concentration and Incidence of Toxicity in Pediatric Patients.
Topics: Anticonvulsants; Child; Humans; Hyperammonemia; Incidence; Thrombocytopenia; Valproic Acid | 2022 |
Valproate-Associated Hyperammonaemic Encephalopathy.
Topics: Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Male; Middle Aged; Neurotoxicity Syndromes; | 2022 |
Risk factors of elevated blood ammonia level in epilepsy patients treated with lamotrigine.
Topics: Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Lamotrigine; Risk Factors; Seizures; Tri | 2022 |
HYPERAMMONAEMIA AND COGNITIVE IMPAIRMENT IN EPILEPSY PATIENTS TREATED WITH VALPROIC ACID - PRELIMINARY STUDY.
Topics: Ammonia; Anticonvulsants; Cognitive Dysfunction; Dementia; Epilepsy; Female; Humans; Hyperammonemia; | 2022 |
Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey.
Topics: Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Risperidone; Valproic Acid | 2023 |
Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey.
Topics: Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Risperidone; Valproic Acid | 2023 |
Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey.
Topics: Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Risperidone; Valproic Acid | 2023 |
Valproic acid-induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey.
Topics: Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Risperidone; Valproic Acid | 2023 |
[A severe, reversible encephalopathy after prolonged use of valproic acid].
Topics: Aged; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Brain Diseases; Epilepsy; Female; Hum | 2023 |
Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation.
Topics: Ammonia; Anticonvulsants; Carnitine; Dietary Supplements; Drug Overdose; Drug-Related Side Effects a | 2023 |
Arginase deficiency-An unheralded cause of developmental epileptic encephalopathy.
Topics: Child; Epilepsy; Epilepsy, Generalized; Humans; Hyperammonemia; Hyperargininemia; Valproic Acid | 2023 |
Valproate-related hyperammonemic encephalopathy with generalized suppression EEG: a case report.
Topics: Adult; Anticonvulsants; Brain Diseases; Electroencephalography; Epilepsy; Female; Humans; Hyperammon | 2023 |
Valproate overdose leading to hyperammonaemic encephalopathy.
Topics: Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Male; Neurotoxicity Syndromes; Valproic Aci | 2023 |
Acute Valproate-Induced Encephalopathy in Status Epilepticus: A Registry-Based Assessment.
Topics: Adult; Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Status Epilepticus; Valproic Acid | 2023 |
Valproate induced carnitine deficiency and hyperammonaemia.
Topics: Amino Acid Metabolism, Inborn Errors; Anticonvulsants; Carnitine; Epilepsy; Humans; Hyperammonemia; | 2023 |
Unusual case of sodium valproate-induced hyperammonaemia encephalopathy.
Topics: Bipolar Disorder; Brain Diseases; Humans; Hyperammonemia; Male; Middle Aged; Neoplasm Recurrence, Lo | 2023 |
Valproicacid-induced hyperammonemic encephalopathy in the emergency department.
Topics: Ammonia; Anticonvulsants; Brain Diseases, Metabolic; Female; Humans; Hyperammonemia; Middle Aged; Re | 2019 |
Fulminant Onset of Valproate-Associated Hyperammonemic Encephalopathy.
Topics: Adult; Anticonvulsants; Brain Diseases; Humans; Hyperammonemia; Male; Valproic Acid | 2019 |
Valproate-induced hyperammonemic encephalopathy: a case report.
Topics: Antimanic Agents; Brain Diseases; Confusion; Female; Gait Ataxia; Humans; Hyperammonemia; Middle Age | 2020 |
Valproic acid and zonisamide induced hyperammonemic encephalopathy.
Topics: Adult; Anticonvulsants; Brain; Brain Diseases; Epilepsy; Humans; Hyperammonemia; Magnetic Resonance | 2020 |
Influence of valproate-induced hyperammonemia on treatment decision in an adult status epilepticus cohort.
Topics: Adult; Aged; Anticonvulsants; Clinical Decision-Making; Cohort Studies; Female; Humans; Hyperammonem | 2020 |
Incidence, Presentation, and Risk Factors for Sodium Valproate-Associated Hyperammonemia in Neurosurgical Patients: A Prospective, Observational Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Female; Humans; Hyperammonemia; Inciden | 2020 |
Managing valproic acid toxicity-related hyperammonaemia: an unpredicted course.
Topics: Adult; Brain Diseases; Carnitine; Drug Overdose; Female; Humans; Hyperammonemia; Valproic Acid; Youn | 2021 |
Hyperammonemia in Patients With Status Epilepticus Treated With or Without Valproic Acid.
Topics: Adult; Ammonia; Anticonvulsants; Humans; Hyperammonemia; Status Epilepticus; Valproic Acid | 2021 |
Valproate-induced fatal acute hyperammonaemia-related encephalopathy in late-onset ornithine transcarbamylase deficiency.
Topics: Adult; Brain Diseases; Humans; Hyperammonemia; Male; Ornithine Carbamoyltransferase Deficiency Disea | 2021 |
Status epilepticus secondary to hyperammonaemia: a late presentation of an undiagnosed urea cycle defect.
Topics: Adult; Child; Humans; Hyperammonemia; Ornithine Carbamoyltransferase Deficiency Disease; Status Epil | 2021 |
L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report.
Topics: Adult; Anticonvulsants; Carnitine; Female; Humans; Hyperammonemia; Seizures; Valproic Acid | 2017 |
Gait instability in valproate-treated patients: Call to measure ammonia levels.
Topics: Accidental Falls; Adult; Ammonia; Anticonvulsants; Disease Progression; Epilepsy, Frontal Lobe; Fema | 2017 |
Burst Suppression Pattern on Electroencephalogram Secondary to Valproic Acid-Induced Hyperammonemic Encephalopathy.
Topics: Adolescent; Anticonvulsants; Autistic Disorder; Brain Diseases; Electroencephalography; Epilepsy; Fe | 2017 |
Effect of acetyl-l-carnitine in elderly patient who presented with hyperammonemia associated with administration of sodium valproate.
Topics: Acetylcarnitine; Aged; Female; GABA Agents; Humans; Hyperammonemia; Valproic Acid; Vitamin B Complex | 2017 |
[Valproate-induced hyperammonemic encephalopathy].
Topics: Acetamides; Anticonvulsants; Brain Diseases, Metabolic; Carnitine; Coma; Drug Therapy, Combination; | 2017 |
Valproate-induced Hyperammonemic Encephalopathy Presenting as Catatonia.
Topics: Adult; Anticonvulsants; Brain Diseases; Catatonia; Epilepsy; Female; Humans; Hyperammonemia; Valproi | 2018 |
Multifactorial non-cirrhotic hyperammonaemic encephalopathy.
Topics: Acetylcysteine; Aftercare; Anti-Bacterial Agents; Bacteremia; Carnitine; Female; Free Radical Scaven | 2018 |
Valproate-induced hyperammonemia - uncovering an underlying inherited metabolic disorder: a case report.
Topics: Anticonvulsants; Critical Illness; Dietary Proteins; Humans; Hyperammonemia; Male; Ornithine Carbamo | 2018 |
Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
Topics: Age Factors; Ammonia; Anticonvulsants; Aspartate Aminotransferases; Chemical and Drug Induced Liver | 2018 |
Severe hyperammonaemic encephalopathy resulting from the overlap between hepatic and valproate encephalopathy.
Topics: Alcoholism; Brain Diseases; Epilepsy; Humans; Hyperammonemia; Hypertension, Portal; Male; Middle Age | 2018 |
Adverse Effects of Treatment with Valproic Acid during the Neonatal Period.
Topics: Anticonvulsants; Chemical and Drug Induced Liver Injury; Consciousness Disorders; Female; Hematologi | 2019 |
Intravenous use of valproic acid in status epilepticus is associated with high risk of hyperammonemia.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Carnitine; Female; Humans; Hyperammonemia; Injectio | 2019 |
Risk factors for hyperammonemia in pediatric patients with epilepsy.
Topics: Acetazolamide; Adolescent; Age Factors; Anticonvulsants; Child; Child, Preschool; Dose-Response Rela | 2013 |
Lacosamide-induced valproic acid toxicity.
Topics: Acetamides; Anticonvulsants; Child, Preschool; Drug Therapy, Combination; Epilepsies, Partial; Femal | 2013 |
A case of valproate-induced hyperammonaemic encephalopathy.
Topics: Aged; Anticonvulsants; Brain Diseases; Female; Humans; Hyperammonemia; Valproic Acid | 2013 |
Hyperammonaemic encephalopathy and a flat electroencephalogram caused by valproic acid.
Topics: Adult; Anesthesia, General; Anticonvulsants; Brain Diseases; Craniocerebral Trauma; Electroencephalo | 2013 |
Valproic acid-induced hyperammonaemic coma and unrecognised portosystemic shunt.
Topics: Anticonvulsants; Coma; Humans; Hyperammonemia; Hypertension, Portal; Liver Diseases, Alcoholic; Male | 2013 |
Valproic acid induced hyperammonaemic encephalopathy.
Topics: Adolescent; Adult; Anticonvulsants; Brain Diseases; Child; Child, Preschool; Cohort Studies; Epileps | 2013 |
Hyperammonemia induced by interaction of valproate and quetiapine.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Drug Interactio | 2013 |
Valproate-induced hyperammonemic encephalopathy followed by benzodiazepine withdrawal in a patient with schizoaffective disorder: a differential diagnosis.
Topics: Anticonvulsants; Benzodiazepines; Delta Rhythm; Diagnosis, Differential; Electroencephalography; Hum | 2013 |
Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Benzo | 2013 |
[Valproate-induced hyperammonemic encephalopathy in a neonate: treatment with carglumic acid].
Topics: Anticonvulsants; Glutamates; Humans; Hyperammonemia; Infant, Newborn; Male; Neurotoxicity Syndromes; | 2014 |
Valproate-related hyperammonemic encephalopathy: report of 1 case.
Topics: Antimanic Agents; Bipolar Disorder; Female; Humans; Hyperammonemia; Neurotoxicity Syndromes; Valproi | 2014 |
Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease).
Topics: Adolescent; Anticonvulsants; Brain Diseases; Carnitine; Drug Therapy, Combination; Female; Humans; H | 2014 |
Valproate-induced hyperammonemic encephalopathy in a renal transplanted patient.
Topics: Adolescent; Anticonvulsants; Brain Diseases; Female; Humans; Hyperammonemia; Kidney Transplantation; | 2014 |
Sodium valproate-related hyperammonaemic encephalopathy.
Topics: Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Male; Middle Aged; Neurotoxicity Syndromes; Valpr | 2014 |
Hyperammonemia associated with valproic acid concentrations.
Topics: Adolescent; Adult; Ammonia; Bipolar Disorder; Carnitine; Child; Dietary Supplements; Dose-Response R | 2014 |
4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.
Topics: Alleles; Amino-Acid N-Acetyltransferase; Ammonia; Anticonvulsants; Asian People; Biomarkers, Pharmac | 2014 |
Ammonium: the deadly toxin you don't want to miss when using mood stabilizers.
Topics: Adult; Aged, 80 and over; Ammonium Compounds; Female; Glutamic Acid; Humans; Hyperammonemia; Male; M | 2013 |
Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ammonia; Anticonvulsants; Antipsychotic Age | 2014 |
Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy.
Topics: Anesthesia, General; Anesthesia, Local; Anticonvulsants; Aphasia; Benzodiazepines; Brain Diseases; B | 2015 |
Carnitine deficiency: Risk factors and incidence in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Cardiomyopathies; Carnitine; Case-Control Studies; Child; Child, Presch | 2015 |
[Hemoperfusion with activated charcoal on valproic acid poisoning. A case report].
Topics: Benzodiazepines; Charcoal; Combined Modality Therapy; Depressive Disorder; Drug Overdose; Female; Fl | 2015 |
Exercises in clinical reasoning: a confusing interaction.
Topics: Adult; Anticonvulsants; Brain Diseases, Metabolic; Clinical Decision-Making; Female; Humans; Hyperam | 2015 |
Reversible weakness and encephalopathy while on long-term valproate treatment due to carnitine deficiency.
Topics: Adult; Antimanic Agents; Brain Diseases; Cardiomyopathies; Carnitine; Female; Humans; Hyperammonemia | 2015 |
Changing incidence of hyperammonemia in Japan from 2006 to 2013: expansion of new antiepileptic drugs reduces the risk of hyperammonemia.
Topics: Adolescent; Adult; Anticonvulsants; Child; Drug Interactions; Drug Therapy, Combination; Epilepsy; F | 2015 |
Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
Topics: Adolescent; Ammonia; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Genotype; Glutamate | 2015 |
Valproic acid-induced hyperammonemia and minimal hepatic encephalopathy prevalence among psychiatric inpatients.
Topics: Adult; Antimanic Agents; Cognitive Dysfunction; Female; Hepatic Encephalopathy; Humans; Hyperammonem | 2016 |
Valproate-induced hyperammonemic encephalopathy associated with urinary tract infection and urinary retention in the psychiatric setting.
Topics: Antimanic Agents; Bipolar Disorder; Brain Diseases; Humans; Hyperammonemia; Male; Middle Aged; Urina | 2016 |
[Acute valproic acid overdose causing only somnolence and stagger despite the extreme hyperammonemia: A case report].
Topics: Acute Disease; Adult; Anticonvulsants; Disorders of Excessive Somnolence; Drug Overdose; Female; Hum | 2016 |
A case with hyperammonemic encephalopathy triggered by single dose valproate.
Topics: Attention Deficit Disorder with Hyperactivity; Brain Diseases; Female; GABA Agents; Humans; Hyperamm | 2016 |
In response: Commentary on clinical significance of CYP2C9-status-guided valproic acid therapy in children.
Topics: Anticonvulsants; Child; Cytochrome P-450 CYP2C9; Epilepsy; Female; Humans; Hyperammonemia; Male; Val | 2016 |
Valproic acid as an antiepileptic drug: Is there a clinical relevance for the epilepsy surgeon?
Topics: Adolescent; Anticonvulsants; Blood Loss, Surgical; Clinical Decision-Making; Drug Resistant Epilepsy | 2016 |
Aripiprazole-related hyponatremia and consequent valproic acid-related hyperammonemia in one patient.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Hyper | 2017 |
Valproate-induced encephalopathy in a comorbid elderly woman.
Topics: Anticonvulsants; Brain Diseases; Comorbidity; Female; Humans; Hyperammonemia; Lethargy; Middle Aged; | 2017 |
Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report.
Topics: Antimanic Agents; Bipolar Disorder; Brain Diseases; Female; Humans; Hyperammonemia; Middle Aged; Val | 2017 |
L-Arginine in the treatment of valproate overdose - five clinical cases.
Topics: Acyl Coenzyme A; Adult; Amino-Acid N-Acetyltransferase; Ammonia; Arginine; Carnitine; Coma; Drug Ove | 2017 |
Lamotrigine might potentiate valproic acid-induced hyperammonemic encephalopathy.
Topics: Aged; Anticonvulsants; Drug Synergism; Female; Humans; Hyperammonemia; Lamotrigine; Neurotoxicity Sy | 2008 |
Valproate-induced hyperammonemic encephalopathy treated by hemodialysis.
Topics: Adolescent; Anticonvulsants; Brain Diseases; Female; Humans; Hyperammonemia; Renal Dialysis; Valproi | 2008 |
Valproate induced non hepatic hyperammonaemic encephalopathy (VNHE)--a study from tertiary care referral university hospital, north India.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Hyperam | 2008 |
[Hyperammoniemia and central pontine myelinolysis in a patient with Sjögren syndrome and chronic valproate use].
Topics: Adult; Antimanic Agents; Female; Humans; Hyperammonemia; Myelinolysis, Central Pontine; Sjogren's Sy | 2008 |
Valproate-induced metabolic changes in patients with epilepsy: assessment with H-MRS.
Topics: Adolescent; Adult; Anticonvulsants; Aspartic Acid; Choline; Creatine; Energy Metabolism; Epilepsies, | 2009 |
Clinical alertness to valproic acid-induced hyperammonemia--two case reports.
Topics: Adult; Antimanic Agents; Brain Diseases, Metabolic; Disease Progression; Electroencephalography; Fem | 2010 |
Valproate-induced reversible pseudoatrophy of the brain and hyperammonemic encephalopathy in a bipolar patient.
Topics: Atrophy; Bipolar Disorder; Brain; Female; Humans; Hyperammonemia; Middle Aged; Neurotoxicity Syndrom | 2009 |
Serum biotinidase activity in children treated with valproic acid and carbamazepine.
Topics: Alanine Transaminase; Ammonia; Anticonvulsants; Aspartate Aminotransferases; Biotinidase; Carbamazep | 2010 |
Valproic acid-induced encephalopathy in very long course treated patients.
Topics: Adolescent; Adult; Anticonvulsants; Brain Damage, Chronic; Dose-Response Relationship, Drug; Female; | 2009 |
Ethical issues and donor numbers.
Topics: Brain Death; Ethics, Clinical; Humans; Hyperammonemia; Male; Tissue and Organ Procurement; Tissue Do | 2010 |
Hyperammoneic encephalopathy, valproic acid, and benzodiazepine withdrawal: a case series.
Topics: Benzodiazepines; Brain Diseases, Metabolic; Drug Administration Schedule; Female; GABA Agents; Human | 2010 |
Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia.
Topics: Adolescent; Adult; Age Distribution; Analysis of Variance; Anticonvulsants; Carbamoyl-Phosphate Synt | 2010 |
[Valproate-induced hyperammonemic encephalopathy].
Topics: Adult; Anticonvulsants; Humans; Hyperammonemia; Male; Neurotoxicity Syndromes; Valproic Acid | 2011 |
Molecular adsorbent recycling system therapy in the treatment of acute valproic acid intoxication.
Topics: Acute Disease; Adult; Antimanic Agents; Charcoal; Drug Overdose; Fluid Therapy; Hemoperfusion; Hepat | 2010 |
Respiratory alkalosis and metabolic acidosis in a child treated with sulthiame.
Topics: Acid-Base Equilibrium; Acidosis; Alkalosis; Anticonvulsants; Carbamazepine; Child; Confusion; Dose-R | 2010 |
Bipolar disorder and valproate-induced hyperammonemic encephalopathy in an adolescent with diabetes.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Diabetes Mellitus, Type 1; Humans; Hyperammonemia; M | 2010 |
Familial hyperinsulinism-hyperammonemia syndrome in a family with seizures: case report.
Topics: Adult; Anticonvulsants; Child, Preschool; Congenital Hyperinsulinism; Family Health; Female; Glutama | 2010 |
New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA.
Topics: Acyl Coenzyme A; Amino-Acid N-Acetyltransferase; Ammonia; Animals; Anticonvulsants; Citrulline; Dise | 2011 |
Cerebellar atrophy in a child with valproate toxicity.
Topics: Anticonvulsants; Atrophy; Cerebellum; Child; Humans; Hyperammonemia; Male; Valproic Acid | 2011 |
[Valproate-induced hyperammononemic encefalopathy].
Topics: Anticonvulsants; Humans; Hyperammonemia; Male; Middle Aged; Neurotoxicity Syndromes; Valproic Acid | 2010 |
Hyperammonemic encephalopathy related to valproate, phenobarbital, and topiramate synergism.
Topics: Drug Synergism; Drug Therapy, Combination; Epilepsy; Female; Fructose; Humans; Hyperammonemia; Middl | 2011 |
Perioperative exacerbation of valproic acid-associated hyperammonemia: a clinical and genetic analysis.
Topics: Adult; Carbamoyl-Phosphate Synthase (Ammonia); Carbamoyl-Phosphate Synthase I Deficiency Disease; Ch | 2011 |
The consequences of valproate overdose.
Topics: Acid-Base Equilibrium; Acidosis, Lactic; Adult; Anticonvulsants; Carnitine; Drug Overdose; Epilepsy; | 2011 |
Carnitine supplementation for valproate-related hyperammonemia to maintain therapeutic valproate level.
Topics: Adult; Anticonvulsants; Antisocial Personality Disorder; Carnitine; Humans; Hyperammonemia; Male; Sc | 2011 |
A case of hyperammonaemic encephalopathy due to valproic acid.
Topics: Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Male; Middle Aged; Neurotoxicity Syndromes; Valpr | 2011 |
Valproate-induced hyperammonemia and seizures: perioperative concerns.
Topics: Anticonvulsants; Humans; Hyperammonemia; Infant; Magnetic Resonance Imaging; Male; Neurotoxicity Syn | 2011 |
Unilateral basal-ganglia involvement likely due to valproate-induced hyperammonemic encephalopathy.
Topics: Anticonvulsants; Basal Ganglia; Brain Diseases; Child, Preschool; Diffusion Magnetic Resonance Imagi | 2012 |
Ammonemia in bipolar patients on maintenance treatment with valproic acid.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Female; Humans; Hyperammonemia; Male; Mood Diso | 2012 |
A severe valproate overdose with complete recovery in a newborn.
Topics: Anticonvulsants; Basal Ganglia; Female; Humans; Hyperammonemia; Infant, Newborn; Magnetic Resonance | 2012 |
Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Female; Humans | 2012 |
A case of valproate-induced encephalopathy.
Topics: Ammonia; Antimanic Agents; Brain Diseases, Metabolic; Female; Humans; Hyperammonemia; Middle Aged; P | 2012 |
[L-carnitine in valproic acid-induced hyperammonemia].
Topics: Adult; Anticonvulsants; Carnitine; Humans; Hyperammonemia; Male; Valproic Acid; Vitamin B Complex | 2014 |
Hyperammonemia associated with valproic acid use in elderly psychiatric patients.
Topics: Aged; Aged, 80 and over; Antimanic Agents; Dementia; Female; Geriatrics; Humans; Hyperammonemia; Mal | 2012 |
A reversible cause of coma in epilepsy.
Topics: Adolescent; Anticonvulsants; Coma; Epilepsy; Female; Humans; Hyperammonemia; Valproic Acid | 2012 |
Valproate (VPA)-associated hyperammonemic encephalopathy independent of elevated serum VPA levels: 21 cases in China from May 2000 to May 2012.
Topics: Adolescent; Adult; Aged; Child, Preschool; China; Epilepsy; Female; Humans; Hyperammonemia; Male; Me | 2013 |
Valproate encephalopathy and hyperammonaemia.
Topics: Aged; Anticonvulsants; Brain Diseases, Metabolic; Female; Humans; Hyperammonemia; Valproic Acid | 2002 |
Valproate-induced encephalopathy: assessment with MR imaging and 1H MR spectroscopy.
Topics: Adult; Anticonvulsants; Aspartic Acid; Brain; Brain Diseases, Metabolic; Choline; Creatine; Epilepsy | 2002 |
Valproate-induced hyperammonaemia.
Topics: Adult; Antimanic Agents; Emergency Services, Psychiatric; Female; Humans; Hyperammonemia; Male; Midd | 2002 |
Valproate-induced hyperammonemic encephalopathy.
Topics: Ammonia; Anticonvulsants; Basal Ganglia Diseases; Brain Diseases, Metabolic; Diagnosis, Differential | 2003 |
Ammonia induced encephalopathy from valproic acid in a bipolar patient: case report.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Coma; Diagnosis, Dual (Psychiatry); Electroencephalograph | 2003 |
Unusual causes of hyperammonemia in the ED.
Topics: Adult; Aged; Anticonvulsants; Antimetabolites, Antineoplastic; Emergency Service, Hospital; Female; | 2004 |
Hyperammonemic encephalopathy induced by a combination of valproate and pivmecillinam.
Topics: Aged; Amdinocillin Pivoxil; Anti-Bacterial Agents; Anticonvulsants; Brain Diseases; Female; Humans; | 2004 |
Valproate-induced hyperammonemic encephalopathy.
Topics: Aggression; Anticonvulsants; Attention Deficit and Disruptive Behavior Disorders; Child; Diagnosis, | 2004 |
Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman.
Topics: Aged; Ammonia; Anticonvulsants; Female; Humans; Hyperammonemia; Platelet Count; Thrombocytopenia; Va | 2004 |
Valproic acid-induced hyperammonemia: a case report.
Topics: Ammonia; Anticonvulsants; Blood Urea Nitrogen; Consciousness Disorders; Diagnosis, Differential; Dru | 2004 |
[Valproate-induced hyperammonemic encephalopathy in a patient with Sjögren's syndrome].
Topics: Anticonvulsants; Epilepsy; Female; Humans; Hyperammonemia; Magnetic Resonance Imaging; Middle Aged; | 2004 |
Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric setting.
Topics: Antimanic Agents; Bipolar Disorder; Brain Diseases; Confusion; Female; Humans; Hyperammonemia; Middl | 2005 |
Topiramate-valproate-induced hyperammonemic encephalopathy syndrome: case report.
Topics: Adolescent; Anticonvulsants; Brain Diseases; Chromosome Inversion; Chromosomes, Human, Pair 15; Drug | 2005 |
Two cases of valproate-induced hyperammonemic encephalopathy without hepatic failure.
Topics: Ammonia; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Female; Fructose; Huma | 2004 |
Valproate-induced hyperammonemic encephalopathy.
Topics: Adult; Brain Diseases, Metabolic; Female; Humans; Hyperammonemia; Male; Valproic Acid | 2005 |
Treatment of valproate-induced hyperammonemia.
Topics: Aged; Antimanic Agents; Humans; Hyperammonemia; Male; Schizophrenia; Treatment Outcome; Valproic Aci | 2005 |
Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy.
Topics: Anticonvulsants; Brain Edema; Carnitine; Drug Overdose; Fatty Acids; Female; Humans; Hyperammonemia; | 2005 |
Efficacy of rapid IV administration of valproic acid for status epilepticus.
Topics: Anticonvulsants; Brain; Dose-Response Relationship, Drug; Drug Administration Schedule; Electroencep | 2005 |
[Hyperammonemia secondary to the use of valproic acid: case report].
Topics: Anticonvulsants; Child; Epilepsy; Humans; Hyperammonemia; Male; Valproic Acid | 2005 |
Acute hyperammonemic coma with chronic valproic acid therapy.
Topics: Anticonvulsants; Coma; Electroencephalography; Epilepsy; Female; Humans; Hyperammonemia; Middle Aged | 2005 |
Fatal cerebral edema from late-onset ornithine transcarbamylase deficiency in a juvenile male patient receiving valproic acid.
Topics: Adolescent; Brain Edema; Fatal Outcome; GABA Agents; Humans; Hyperammonemia; Male; Ornithine Carbamo | 2006 |
Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.
Topics: Adolescent; Aged; Anticonvulsants; Brain Diseases; Child, Preschool; Female; Humans; Hyperammonemia; | 2006 |
Hippocampal involvement in valproate-induced acute hyperammonemic encephalopathy.
Topics: Brain Diseases, Metabolic; Female; Hippocampus; Humans; Hyperammonemia; Middle Aged; Valproic Acid | 2006 |
Polydipsia with normal natremia induced by Valproic Acid.
Topics: Anticonvulsants; Drinking; Humans; Hyperammonemia; Male; Middle Aged; Valproic Acid | 2006 |
Case report: valproic Acid and risperidone treatment leading to development of hyperammonemia and mania.
Topics: Antipsychotic Agents; Asperger Syndrome; Attention Deficit Disorder with Hyperactivity; Bipolar Diso | 2007 |
Clinical utility of a continuous intravenous infusion of valproic acid in pediatric patients.
Topics: Administration, Oral; Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combinatio | 2007 |
Different clinical manifestations of hyperammonemic encephalopathy.
Topics: Adult; Anticonvulsants; Brain Diseases, Metabolic; Drug Therapy, Combination; Electroencephalography | 2007 |
Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy.
Topics: Adult; Ammonia; Anticonvulsants; Brain; Electroencephalography; Hepatic Encephalopathy; Humans; Hype | 2007 |
Hyperammonemia and valproic acid-induced encephalopathy.
Topics: Brain Diseases; Humans; Hyperammonemia; Protein Binding; Valproic Acid | 2007 |
[Valproate-associated hyperammonemic encephalopathy. Report of one case].
Topics: Aged; Anticonvulsants; Brain Diseases; Female; Humans; Hyperammonemia; Valproic Acid | 2007 |
[Metabolic encephalopathy can be a potentially life-threatening complication from valproic acid].
Topics: Aged, 80 and over; Ammonia; Brain Diseases, Metabolic; Consciousness Disorders; Diagnosis, Different | 2008 |
Postictal transient hyperammonemia.
Topics: Adult; Anticonvulsants; Epilepsy, Tonic-Clonic; Humans; Hyperammonemia; Liver Function Tests; Male; | 2008 |
Two cases of valproic acid poisoning treated with L-carnitine.
Topics: Adolescent; Adult; Anticonvulsants; Antidotes; Carnitine; Depression; Drug Overdose; Female; Humans; | 2007 |
A case of hyperammonemic encephalopathy after 11 years of valproate therapy.
Topics: Aged; Anticonvulsants; Bipolar Disorder; Delayed-Action Preparations; Drug Therapy, Combination; Hum | 2008 |
[Encephalopathy induced by ingestion of ammonium during valproate therapy].
Topics: Brain Diseases; Diet; Drug Interactions; Female; Humans; Hyperammonemia; Middle Aged; Quaternary Amm | 2001 |
Simultaneous side effects of both clozapine and valproate.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Carnitine; Clozapine; Coma; Diabetic Ketoacidosis; Dru | 2001 |
Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy.
Topics: Adult; Anticonvulsants; Coma; Humans; Hyperammonemia; Liver; Liver Failure; Male; Valproic Acid | 2001 |
[Hyperammonaemic coma after valproate therapy as adult onset of ornithine transcarbamylase deficiency].
Topics: Coma; Female; Humans; Hyperammonemia; Middle Aged; Ornithine Carbamoyltransferase Deficiency Disease | 2002 |
Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy.
Topics: Adolescent; Adult; Ammonia; Anticonvulsants; Brain; Brain Diseases; Electroencephalography; Female; | 2002 |
Topiramate enhances the risk of valproate-associated side effects in three children.
Topics: Affective Symptoms; Anticonvulsants; Chemical and Drug Induced Liver Injury; Drug Therapy, Combinati | 2002 |
Fulminant progression of hyperammonaemic encephalopathy after treatment with valproate in a patient with ureterosigmoidostomy.
Topics: Adult; Ammonia; Anastomosis, Surgical; Anticonvulsants; Brain Diseases, Metabolic; Colon, Sigmoid; F | 2002 |
Deepening coma in an epileptic patient: the missing link to the urea cycle. Hyperammonaemic metabolic encephalopathy.
Topics: Anticonvulsants; Atrophy; Cerebellum; Coma; Epilepsy; Female; Humans; Hyperammonemia; Middle Aged; T | 2002 |